Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

PFE

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

PFE

AI Research Report

Powered by Claude

Ready to analyze PFE

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

D
Stonvex Quant Grade
21.8/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
D
27 / 100

Today's volume vs prior session average.

Volatility
C-
31 / 100

Absolute daily price move vs peers.

News Flow
F
13 / 100

24h article count relative to the universe.

Sentiment
D
23 / 100

AI-classified polarity of recent news.

Dollar Flow
F
10 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
D
21 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Healthcare →
LLY
Eli Lilly
$810.50
+2.30%
UNH
UnitedHealth
$485.20
-2.51%
NVO
Novo Nordisk
—
—
JNJ
Johnson & Johnson
—
—
TMO
Thermo Fisher
—
—
WELL
Welltower
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

whgksdhr1111@naver.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Pfizer Inc

Pfizer Inc

Pharmaceuticals·NEW YORK STOCK EXCHANGE, INC.·US·IPO 1944-01-17

Analyst Consensus

Buy
Based on 35 analysts
Period: 2026-04-01
15 Buy (43%)17 Hold (49%)3 Sell (9%)
Rating Distribution
Strong Buy
6
Buy
9
Hold
17
Sell
2
Strong Sell
1
Trend
2026-04
15/17/3
2026-03
14/18/3
2026-02
15/17/1
2026-01
15/17/1
📅 Earnings in 21d (May 5)
NEW YORK STOCK EXCHANGE, INC.After-hours
Pfizer Inc
Pharmaceuticals
$27.11
$-0.23 (-0.84%)
After-hrs · vs prev close $27.34
Open
$27.20
Prev close
$27.34
Day range
$27.07 – $27.31
52W range
$21.09 – $28.75
Mkt cap
$155.52B
P/E
19.9
EPS
$1.36
Beta
0.35

Fundamentals

Valuation
Market Cap
$155.52B
P/E (TTM)
19.90S&P avg ~22
P/S (TTM)
2.47S&P avg ~2.8
P/B
1.64S&P avg ~4.5
P/FCF
15.04S&P avg ~26
EPS (TTM)
$1.36
Book/sh
$15.21
Cash/sh
$2.39
Profitability
Gross Margin
75.81%avg ~45%
Operating Margin
15.43%avg ~15%
Net Margin
12.42%avg ~12%
ROE
8.68%avg ~18%
ROA
3.74%avg ~7%
ROI
5.11%
Payout Ratio
98.75%
FCF/sh
—
Growth & Health
Rev Growth YoY
-1.64%
Rev Growth 5Y
8.48%
EPS Growth YoY
-3.46%
EPS Growth 5Y
-3.51%
Current Ratio
—
Quick Ratio
0.87
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
0.35
52W High
$28.75
52W Low
$21.09
Avg Vol (10D)
37.13M
Avg Vol (3M)
45.26M
Div Yield
6.29%
Div/sh (TTM)
—
Analyst
Buy (35)
Price Performance
5D+0.89%
MTD-2.64%
3M+8.11%
6M+3.44%
YTD+9.80%
1Y+26.63%

Factor Grades

View details →
C+
Overall score: 58/100
B+
Valuation
D+
Growth
B-
Profitability
B-
Momentum
C+
Financial Health
  • Yahoo·7h ago

    Investing $8,000 In Each of These 3 Stocks in 2026 Could Generate $1,500 in Annual Dividends

    These stocks have been struggling in recent years, but they are safer investments than they appear to be at first glance.

  • Yahoo·8h ago

    Build a Six Figure Dividend Stream With Four Blue Chip Names and $2 Million

    Two million dollars in four household-name dividend payers can generate between $132,000 and $146,000 in annual income. That is the income profile of the moderate yield tier, where Enterprise Products Partners L.P. (NYSE:EPD), Pfizer Inc. (NYSE:PFE), Altria Group (NYSE:MO), and Verizon Communications (NYSE:VZ) currently sit. The real question is whether $2 million is right for ... Build a Six Figure Dividend Stream With Four Blue Chip Names and $2 Million

  • Yahoo·9h ago

    Four Tickers That Turn $1 Million Into $60,000 of Annual Income

    A million dollars sounds like enough to retire on. Whether it actually is depends entirely on what you make it do. At a blended yield of roughly 6%, $1,000,000 produces exactly $60,000 per year in investment income. Four tickers currently sitting in that yield range are Pfizer Inc (NYSE:PFE), Altria Group (NYSE:MO), Verizon Communications Inc ... Four Tickers That Turn $1 Million Into $60,000 of Annual Income

  • Yahoo·23h ago

    Pfizer (PFE) Outperforms Broader Market: What You Need to Know

    Pfizer (PFE) reached $27.34 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.

  • Benzinga·1d ago

    UBS Maintains Neutral on Pfizer, Raises Price Target to $27

    UBS analyst Michael Yee maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $25 to $27.

  • Yahoo·1d ago

    How Eli Lilly Stock Rises To $2,000

    Can Eli Lilly (NYSE: LLY) stock reach $2,000 in the coming years? We think there is a real possibility. How? Consider this, just about a year ago, Eli Lilly stock was trading at around $754 levels, and the stock has gained 25% and trades at about $939 per share currently. Looking at the valuations, Eli Lilly’s valuation is about 39x based on trailing adjusted earnings of $24.21 and about 27x estimated 2026 earnings. Is this pricey? Not really, considering the company’s heady earnings growth and

  • SeekingAlpha·1d ago

    My Top 4 Pharma Picks Under Rising Geopolitical Risk

    Discover 4 under-the-radar Big Pharma stocks beating earnings forecasts, offering high dividend yields, and positioned for success. Click for the picks!

  • Yahoo·1d ago

    Frontier Medicines Appoints Veteran Drug Development Leader David R. Epstein to Board of Directors

    BOSTON & SOUTH SAN FRANCISCO, Calif., April 13, 2026--Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced the appointment of David R. Epstein to its board of directors. Mr. Epstein currently serves as chairman and chief executive officer of Ottimo Pharma and was most recently chief executive officer of Seagen, where he led

  • View all news →
⚠️
Dilution risk detected

3 offering-related filings in the last 60 filings. Latest: 424B5 on 2025-11-20. View all →

Recent insider activity

View all →
  • 4Insider transaction
    13d ago
  • 4Insider transaction
    15d ago
  • 4Insider transaction
    15d ago
  • 4Insider transaction
    15d ago
  • 4Insider transaction
    15d ago